| Literature DB >> 28277044 |
Michael Harris1, Peter Frey2, Magdalena Esteva3, Svjetlana Gašparović Babić4, Mercè Marzo-Castillejo5, Davorina Petek6, Marija Petek Ster6, Hans Thulesius7.
Abstract
OBJECTIVE: European cancer survival rates vary widely. System factors, including whether or not primary care physicians (PCPs) are gatekeepers, may account for some of these differences. This study explores where patients who may have cancer are likely to present for medical care in different European countries, and how probability of presentation to a primary care clinician correlates with cancer survival rates.Entities:
Keywords: Europe; Health care systems; cancer; decision making; diagnosis; primary health care
Mesh:
Year: 2017 PMID: 28277044 PMCID: PMC5361416 DOI: 10.1080/02813432.2017.1288692
Source DB: PubMed Journal: Scand J Prim Health Care ISSN: 0281-3432 Impact factor: 2.581
List of participating consensus groups, with national 1-year relative cancer survival rates.
| Country | Region represented in survey | Number of cliniciansin consensus group | EUROCARE-5 national 1-year relativesurvival rate for all adult cancers (%) |
|---|---|---|---|
| Bulgaria | Plovdiv | 9 | 60.0 |
| Croatia | Primorsko-goranska county | 4 | 63.8 |
| Denmark | Denmark | 5 | 69.9 |
| England | The West of England | 4 | 66.9 |
| France | North of Paris and northern suburb of Paris | 7 | 78.2 |
| Germany | North Rhine-Westphalia | 3 | 77.3 |
| Mittelhessen | 3 | ||
| Italy | Caserta, Southern Italy | 3 | 74.1 |
| Norway | Norway | 3 | 75.5 |
| Poland | Białystok-Podlasie | 5 | 63.8 |
| Kujawsko-Pomorskie | 4 | ||
| Scotland | Northeast of Scotland | 3 | 64.4 |
| Slovenia | Central region | 4 | 69.3 |
| Spain | Mallorca | 7 | 71.5 |
| Barcelona | 3 | ||
| Sweden | Sweden | 7 | 80.5 |
| Switzerland | Kanton Bern | 4 | 78.4 |
Mean probability of presentation to each clinician for each participating country.
| A primary care physician/family doctor | A practice nurse (a nurse working in a primary care practice) | A specialist doctor outside a hospital | A specialist doctor in a hospital | A specialist nurse outside a hospital | A specialist nurse in a hospital | A hospitalemergency department | Another clinician | |
|---|---|---|---|---|---|---|---|---|
| Bulgariaa | 0.43 | 0.00 | 0.20 | 0.13 | 0.00 | 0.00 | 0.14 | 0.10 |
| Croatia | 0.47 | 0.00 | 0.15 | 0.06 | 0.00 | 0.00 | 0.23 | 0.09 |
| Denmark | 0.95 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| England | 0.39 | 0.17 | 0.00 | 0.00 | 0.09 | 0.00 | 0.23 | 0.12 |
| France | 0.39 | 0.00 | 0.16 | 0.08 | 0.04 | 0.02 | 0.13 | 0.19 |
| Germany | 0.36 | 0.00 | 0.32 | 0.05 | 0.10 | 0.01 | 0.11 | 0.05 |
| Italy | 0.58 | 0.00 | 0.21 | 0.19 | 0.00 | 0.00 | 0.03 | 0.00 |
| Norway | 0.56 | 0.00 | 0.15 | 0.00 | 0.06 | 0.06 | 0.00 | 0.18 |
| Poland | 0.39 | 0.03 | 0.29 | 0.10 | 0.07 | 0.00 | 0.11 | 0.00 |
| Scotland | 0.40 | 0.30 | 0.00 | 0.00 | 0.09 | 0.00 | 0.20 | 0.00 |
| Slovenia | 0.48 | 0.03 | 0.17 | 0.03 | 0.08 | 0.00 | 0.06 | 0.16 |
| Spain | 0.37 | 0.05 | 0.09 | 0.04 | 0.04 | 0.03 | 0.24 | 0.14 |
| Sweden | 0.47 | 0.14 | 0.11 | 0.05 | 0.07 | 0.03 | 0.02 | 0.11 |
| Switzerland | 0.43 | 0.05 | 0.28 | 0.06 | 0.00 | 0.00 | 0.19 | 0.00 |
Bulgaria: Patients with COPD are under the surveillance of chest specialists, allowing direct access; neither nurses nor midwives are able to diagnose or prescribe; some PCPs are qualified in internal medicine, but few are qualified in gynaecology.
Croatia: Some patients present directly to a primary care emergency department.
England: Some patients present directly to heath visitor, or to a primary care emergency department.
France does not have practice nurse or specialist nurse systems; the PMI (Protection Maternal et Infantile) system is responsible for prevention of maternal problems.
Germany does not have practice nurse or specialist nurse systems; probability of presentation to a specialist depends on waiting times (higher probability if shorter waiting time).
Norway: Some patients present directly to a primary care emergency department.
In Poland, COPD and some other chronic conditions are usually managed by specialists. However, if the waiting time for a specialist is longer, a patient is more likely to see a PCP.
Slovenia: Patients may be seen in a primary care emergency department.
Spain: There is regional variation in the proportion of patients who first present to a specialist.
In Sweden, a 24-hour-a-day health hotline may be the initial point of contact.
Probability of presentation to each clinician group for all four vignettes combined and correlation between the probability of initial presentation to each clinician group and each country’s 1-year overall relative cancer survival.
| Clinician group | Probability of presentation (range) | Pearson’s correlation coefficient (95% CI) |
|---|---|---|
| Primary care clinician | 0.48 (0.28–0.95) | −0.16 (−0.39, 0.08) |
| Specialist doctor | 0.24 (0–0.47) | −0.04 (−0.27, 0.20) |
| Specialist nurse | 0.08 (0–0.13) | 0.45 |
| Emergency department | 0.12 (0–0.25) | −0.33 |
p < 0.05.
Figure 1.Box and whisker plot of overall probability of presentation to each clinician group.
Correlations, for individual vignettes, between probability of initial presentation to each clinician group and national cancer 1-year relative cancer survival.
| Pearson’s correlation coefficient (95% CI) for each clinician group | ||||
|---|---|---|---|---|
| Vignette | Primary care clinician | Specialist doctor | Specialist nurse | Emergency department |
| Possible lung cancer | −0.57a (−0.83, −0.12) | 0.55a (0.09, 0.81) | −0.28 (−0.67 to 0.24) | 0.06 (−0.43, 0.53) |
| Possible ovarian cancer | −0.13 (−0.57, 0.38) | 0.08 (−0.42, 0.54) | 0.40 (−0.10, 0.74) | −0.46 (−0.77, 0.03) |
| Possible breast cancer | 0.14 (−0.36, 0.58) | −0.13 (−0.57, 0.38) | 0.11 (−0.39, 0.66) | −0.06 (−0.53, 0.43) |
| Possible colorectal cancer | 0.20 (−0.31 to 0.62) | −0.04 (−0.51 to 0.45) | −0.11 (−0.56, 0.39) | −0.13 (−0.57, 0.37) |
p < 0.05.
Figure 2.Correlations for individual vignettes between probability of initial presentation to a primary care clinician and national 1-year relative cancer survival rates, with 95% confidence intervals.